Cellectis Presents Promising Results for its eti-cel Candidate at the ASH Congress 2025
At the annual Congress of the American Society of Hematology, Cellectis presented preliminary data on its eti-cel product, indicating an overall response rate of 88% for the treatment of non-Hodgkin's lymphoma.
Preliminary Clinical Trial Results Unveiled
Cellectis, a biotechnology company specializing in genome editing, unveiled preliminary results of its phase 1 clinical trial, NATHALI-01, at the 67th Congress of the American Society of Hematology (ASH) in Orlando. The trial evaluates the candidate product eti-cel, a dual CAR allogeneic treatment targeting CD20 and CD22, in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). According to Cellectis' statement, the results show an overall response rate (ORR) of 88% and a complete response rate (CR) of 63% at the current dose level.
Exploring the Addition of Exogenous Low-Dose Interleukin-2
The company plans to explore the effect of an exogenous addition of low-dose interleukin-2 (IL-2), which could enhance the expansion and persistence of CAR-T cells. 'Cellectis believes that this addition could deepen the already high response rates observed with eti-cel,' stated Adrian Kilcoyne, Cellectis' Medical Director. The next step will be to analyze the potential impact of this addition on the treatment, with recruitments planned in the IL-2 cohort starting the first quarter of 2026.
Highlighting the Potential of This Approach
According to Cellectis, these preliminary results highlight the potential of this approach to improve the management of relapsed patients. The company plans to share the complete phase 1 data in 2026, once the studies have advanced. Cellectis is headquartered in Paris, with facilities in New York and Raleigh. The company is listed on Euronext Growth and Nasdaq.
